Get the Stockscreener App
1.122
1.75%
-0.02
Enlivex Therapeutics Ltd Stock (ENLV) Forecast
The Enlivex Therapeutics Ltd (ENLV) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $1.7933, representing a +59.83% increase from the current price of $1.122. The highest analyst price target is $1.8524, and the lowest is $1.7342.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ENLV Price Target
Average 12.05
(+974.06% Upside)
Is Enlivex Therapeutics Ltd (ENLV) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.60 | Neutral |
| STOCH(9,6) | 9.364 | Buy |
| STOCHRSI(14) | 7.7493 | Buy |
| MACD(12,26) | 0.0183 | Sell |
| ADX(14) | 36.66 | Buy |
| William %R | -99.23 | Buy |
| CCI(14) | -109.40 | Sell |
Buy: 4
Sell: 2
Neutral: 1
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.1934
Sell
|
1.1781
Sell
|
| MA20 |
1.1997
Sell
|
1.1747
Sell
|
| MA50 |
1.0833
Buy
|
1.1194
Buy
|
| MA100 |
1.0515
Buy
|
1.1008
Buy
|
| MA200 |
1.1311
Sell
|
1.2027
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, ENLV could be considered a Neutral, with 17 technical analysis indicators signaling 8 Buy signals, 8 signaling Sell signals and 1 Neutral signals. This suggests that investors should exercise caution when entering new positions on ENLV, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 44.6 indicates that ENLV is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 9.364 indicates that ENLV is oversold. This indicates that ENLV price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 7.7493 indicates that ENLV is oversold. This suggests that ENLV price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 36.66 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -109.4 indicates that ENLV is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term ENLV price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Enlivex Therapeutics Ltd financial reports and earnings history, Enlivex Therapeutics Ltd (ENLV) stock could reach $5.9544 by 2030, $5.9479 by 2040 and $18.45 by 2050. See the projected annual prices until 2050 of the Enlivex Therapeutics Ltd stock below:
- Enlivex Therapeutics Ltd (ENLV) is expected to reach an average price of $2.2532 in 2035, with a high prediction of $3.0307 and a low estimate of $2.5132. This indicates an $100.82% rise from the last recorded price of $1.122.
- Enlivex Therapeutics Ltd (ENLV) stock is projected to chart a bullish course in 2040, with an average price target of $6.0801, representing an $441.90% surge from its current level. The forecast ranges from a conservative $6.1852 to a sky-high $5.9479.
- Our analysts predict Enlivex Therapeutics Ltd (ENLV) to jump 885.45% by 2045, soaring from $10.83 to an average price of $11.06, potentially reaching $10.79. While $10.83 is the low estimate, the potential upside is significant.
- Enlivex Therapeutics Ltd (ENLV) stock is expected to climb by 2050, reaching an average of $18.06, a $1,510% jump from its current level. However, a wide range of estimates exists, with high and low targets of $18.45 and $18.47, respectively, highlighting the market's uncertainty.
Enlivex Therapeutics Ltd Stock (ENLV) Year by Year Forecast
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2025
Enlivex Therapeutics Ltd Stock (ENLV) is expected to reach an average price of $4.585 in 2025, with a high prediction of $9.143 and a low estimate of $0.027. This indicates an +308.65% rise from the last recorded price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| August, 2025 | $2.0765 | $1.7342 | $1.8524 | +85.07% |
| September, 2025 | $1.8728 | $1.7746 | $1.4628 | +66.91% |
| October, 2025 | $2.0231 | $1.9389 | $1.7731 | +80.31% |
| November, 2025 | $0.9594 | $1.8412 | $1.8672 | -14.50% |
| December, 2025 | $4.2803 | $1.0466 | $8.1625 | +281.49% |
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2026
The predicted value for Enlivex Therapeutics Ltd (ENLV) in 2026 is set at an average of $12.15. Estimates vary from a peak of $23.06 to a trough of $1.2419, indicating an +982.76% surge from the present price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.964 | $1.2419 | $5.6662 | +75.05% |
| February, 2026 | $4.3478 | $1.4259 | $7.1659 | +287.50% |
| March, 2026 | $4.0415 | $1.7696 | $4.813 | +260.21% |
| April, 2026 | $11.59 | $4.2474 | $23.06 | +933.08% |
| May, 2026 | $7.3149 | $5.103 | $12.20 | +551.95% |
| June, 2026 | $5.6087 | $3.9768 | $7.6209 | +399.88% |
| July, 2026 | $3.4083 | $2.3183 | $6.4665 | +203.77% |
| August, 2026 | $3.6721 | $3.1521 | $4.3743 | +227.28% |
| September, 2026 | $2.4317 | $1.6317 | $4.268 | +116.73% |
| October, 2026 | $2.6255 | $1.5036 | $3.5055 | +134.00% |
| November, 2026 | $8.3192 | $2.9414 | $8.4092 | +641.46% |
| December, 2026 | $4.2999 | $4.2889 | $8.1851 | +283.23% |
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Enlivex Therapeutics Ltd (ENLV) is $2.3322, with a high forecast of $4.6548 and a low forecast of $0.00962. This indicates an +107.86% increase from the last price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.2026 | $2.8426 | $4.6548 | +185.44% |
| February, 2027 | $2.7663 | $2.5263 | $4.1145 | +146.55% |
| March, 2027 | $1.196 | $0.7861 | $2.7323 | +6.60% |
| April, 2027 | $0.8997 | $0.6079 | $1.8301 | -19.81% |
| May, 2027 | $0.0835 | $0.0675 | $1.1057 | -92.56% |
| June, 2027 | $0.2131 | $0.0294 | $0.7273 | -81.00% |
| July, 2027 | $0.9569 | $0.1291 | $1.0969 | -14.72% |
| August, 2027 | $2.1506 | $0.8928 | $4.0587 | +91.68% |
| September, 2027 | $0.3203 | $0.4897 | $1.9883 | -71.45% |
| October, 2027 | $0.306 | $0.1219 | $1.1022 | -72.73% |
| November, 2027 | $1.4078 | $0.0878 | $1.4878 | +25.47% |
| December, 2027 | $1.0274 | $0.00962 | $1.3537 | -8.43% |
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2028
In 2028, Enlivex Therapeutics Ltd (ENLV) is projected to reach an average price of $1.1087, with a high projection of $2.1393 and a low estimate of $0.0782. This indicates an -1.18% fall from the last price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.2012 | $0.7593 | $2.1393 | +7.06% |
| February, 2028 | $0.3949 | $0.229 | $1.533 | -64.80% |
| March, 2028 | $0.5646 | $0.1268 | $0.7007 | -49.68% |
| April, 2028 | $1.0383 | $0.3864 | $1.2724 | -7.46% |
| May, 2028 | $0.398 | $0.318 | $1.2542 | -64.53% |
| June, 2028 | $0.7617 | $0.1539 | $1.0358 | -32.11% |
| July, 2028 | $1.0654 | $0.7276 | $1.3653 | -5.04% |
| August, 2028 | $0.4751 | $0.4751 | $1.0915 | -57.66% |
| September, 2028 | $0.1912 | $0.2829 | $0.7488 | -82.96% |
| October, 2028 | $0.2074 | $0.1866 | $0.1748 | -81.51% |
| November, 2028 | $0.1728 | $0.1914 | $0.2065 | -84.60% |
| December, 2028 | $0.0867 | $0.0782 | $0.2041 | -92.27% |
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2029
The 2029 price forecast for Enlivex Therapeutics Ltd Stock (ENLV) is $3.0912 on average, with a high prediction of $6.17 and a low estimate of $0.0125. This represents an +175.51% increase from the previous price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.0244 | $0.1544 | $0.1917 | -97.83% |
| February, 2029 | $0.1006 | $0.0125 | $0.5916 | -91.03% |
| March, 2029 | $0.4869 | $0.1587 | $0.0872 | -56.61% |
| April, 2029 | $0.8631 | $0.869 | $0.7331 | -23.07% |
| May, 2029 | $0.3535 | $0.6216 | $0.8353 | -68.50% |
| June, 2029 | $0.2397 | $0.2523 | $0.3275 | -78.63% |
| July, 2029 | $0.764 | $0.3138 | $1.4181 | -31.91% |
| August, 2029 | $0.9937 | $0.6937 | $2.0499 | -11.44% |
| September, 2029 | $1.3374 | $0.7655 | $1.7974 | +19.20% |
| October, 2029 | $2.1071 | $1.1033 | $2.7711 | +87.80% |
| November, 2029 | $0.1492 | $0.1651 | $3.0689 | -86.70% |
| December, 2029 | $7.38 | $0.0527 | $6.17 | +557.75% |
Enlivex Therapeutics Ltd Stock (ENLV) Price Forecast for 2030
Enlivex Therapeutics Ltd Stock (ENLV) is expected to reach an average price of $14.06 in 2030, with a high forecast of $28.01 and a low forecast of $0.1069. This signifies an +1,153% surge from the last price of $1.122.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.5227 | $6.4107 | $5.9544 | +35.71% |
| February, 2030 | $5.4868 | $0.1069 | $6.4868 | +389.02% |
| March, 2030 | $5.1443 | $0.2395 | $12.04 | +358.49% |
| April, 2030 | $10.70 | $3.4811 | $11.76 | +853.81% |
| May, 2030 | $9.6711 | $8.2592 | $28.01 | +761.95% |
| June, 2030 | $8.8814 | $7.467 | $11.61 | +691.57% |
| July, 2030 | $8.5921 | $8.8521 | $9.7877 | +665.78% |
| August, 2030 | $6.4046 | $7.6846 | $7.7165 | +470.82% |
| September, 2030 | $7.4572 | $7.2528 | $7.0506 | +564.63% |
| October, 2030 | $7.4358 | $7.3134 | $7.7897 | +562.73% |
| November, 2030 | $10.71 | $7.485 | $9.2404 | +854.58% |
| December, 2030 | $10.44 | $10.73 | $10.49 | +830.74% |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):